Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.

The pharmacogenomics journal - 1 Dec 2017

Spracklen T F, Vorster A A, Ramma L, Dalvie S, Ramesar R S

Abstract excerpt

Ototoxicity is a disabling reaction to cisplatin chemotherapy. Much of the inter-individual variability in the development of hearing impairment among cisplatin-receiving patients has not been fully accounted for. In particular, little is known about the pharmacogenomics of cisplatin-induced ototoxicity. This study sought to investigate the role of variation in five candidate genes in a cohort of South African...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Audiometry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Cohort Studies

Share to Dose-Response Relationship, Drug

Share to Hearing Loss

Share to NF-E2-Related Factor 2

Share to Pharmacogenomic Variants

Source

Identifiers

PMID: 27457817
DOI: 10.1038/tpj.2016.52

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.PMID 27457817Read ↗

Genetic variation in Otos is associated with cisplatin-induced ototoxicity.Semantic proximity Read ↗

Pharmacogenomics of cisplatin-induced ototoxicity.Semantic proximity Read ↗

Genetic variants associated with cisplatin-induced ototoxicity.Semantic proximity Read ↗

Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.Semantic proximity Read ↗

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.Semantic proximity Read ↗

Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity.Semantic proximity Read ↗

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.Semantic proximity Read ↗

The association between DNA repair genes polymorphisms and cisplatin-induced ototoxicity in cancer patients: a systematic review.Semantic proximity Read ↗

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.Semantic proximity Read ↗

Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.Semantic proximity Read ↗

Systematic Review and Meta-Analysis of the Influence of Genetic Variation on Ototoxicity in Platinum-Based Chemotherapy.Semantic proximity Read ↗

SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.